KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Accured Expenses (2017 - 2026)

Aquestive Therapeutics has reported Change in Accured Expenses over the past 9 years, most recently at $5.1 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 455.68% year-over-year to $5.1 million; the TTM value through Dec 2025 reached $3.0 million, up 303.22%, while the annual FY2025 figure was $3.0 million, 303.22% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $5.1 million at Aquestive Therapeutics, up from $118000.0 in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $5.1 million in Q4 2025 and troughed at -$4.0 million in Q1 2022.
  • A 5-year average of -$210050.0 and a median of $46500.0 in 2022 define the central range for Change in Accured Expenses.
  • On a YoY basis, Change in Accured Expenses climbed as much as 3916.0% in 2023 and fell as far as 160.3% in 2023.
  • Year by year, Change in Accured Expenses stood at $1.2 million in 2021, then tumbled by 102.08% to -$25000.0 in 2022, then surged by 3916.0% to $954000.0 in 2023, then dropped by 3.98% to $916000.0 in 2024, then surged by 455.68% to $5.1 million in 2025.
  • Business Quant data shows Change in Accured Expenses for AQST at $5.1 million in Q4 2025, $118000.0 in Q3 2025, and $600000.0 in Q2 2025.